Agios Pharmaceuticals Inc Bevétel Y / Y
Mi az Agios Pharmaceuticals Inc Bevétel Y / Y?
A Bevétel Y / Y az Agios Pharmaceuticals Inc - 55.39%
Mi a Bevétel Y / Y meghatározása?
Az elmúlt 3 évben az éves bevételnövekedés a bevételek növekedése az elmúlt 3 év átlagában az elmúlt 3 évben.
The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.
Bevétel Y / Y a Health Care szektor a NASDAQ-on cégekben a Agios Pharmaceuticals Inc -hoz képest
Mit csinál Agios Pharmaceuticals Inc?
at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible
bevétel y / y -hoz hasonló cégek Agios Pharmaceuticals Inc
- Tata Motors nak Bevétel Y / Y 55.10% van
- Tourism Finance of India nak Bevétel Y / Y 55.14% van
- Genesys International nak Bevétel Y / Y 55.21% van
- New Residential Investment Corp nak Bevétel Y / Y 55.22% van
- Trisura nak Bevétel Y / Y 55.32% van
- Wilmington Capital Management nak Bevétel Y / Y 55.35% van
- Agios Pharmaceuticals Inc nak Bevétel Y / Y 55.39% van
- Kings Infra Ventures nak Bevétel Y / Y 55.44% van
- Photon Control nak Bevétel Y / Y 55.49% van
- Lumax Industries nak Bevétel Y / Y 55.51% van
- Scholar Education nak Bevétel Y / Y 55.51% van
- Crestwood Equity Partners LP nak Bevétel Y / Y 55.56% van
- Geekay Wires nak Bevétel Y / Y 55.61% van